Salix Pharma (SLXP) Receives Subpoena in NY for Xifaxan, Relistor, Apriso Marketing

February 12, 2013 5:00 PM EST
Get Alerts SLXP Hot Sheet
Trade SLXP Now!
Join SI Premium – FREE
On February 1, 2013, Salix Pharmaceuticals Ltd (Nasdaq: SLXP) a wholly owned subsidiary of Salix Pharmaceuticals, Ltd. , received a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting documents regarding the Company’s sales and promotional practices for Xifaxan® (rifaximin), Relistor® (methylnaltrexone bromide) and Apriso® (mesalamine). The Company is in the process of responding to the subpoena and intends to cooperate fully with the subpoena and related government investigation. The Company cannot predict or determine the impact of this inquiry on our financial condition or results of operations.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Hot Corp. News, Litigation

Add Your Comment